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Patients with non-small cell lung cancer frequently demonstrate differing clinical courses, even when they express
the same tumour stage. Additional markers of prognostic significance could allow further stratification of treatment
for these patients. By generating quantitative information about tumour heterogeneity as reflected by the
distribution of pixel values within the tumour, CT texture analysis (CTTA) can provide prognostic information for
patients with NSCLC. In addition to describing the practical application of CTTA to NSCLC, this article discusses a
range of issues that need to be addressed when CTTA is included as part of routine clinical care as opposed to its
use in a research setting. The use of quantitative imaging to provide prognostic information is a new and exciting
development within cancer imaging that can expand the imaging specialist’s existing role in tumour evaluation.
Derivation of prognostic information through the application of image processing techniques such as CTTA, to
images acquired as part of routine care can help imaging specialists make best use of the technologies they deploy
for the benefit of patients with cancer.
Background
Lung cancer remains the leading cause of cancer
death in Western societies, with more than 75 % of
cases comprising non-small cell lung cancer (NSCLC).
Tumour stage is the most important prognostic vari-
able for survival, and this parameter makes a major
contribution to clinical decisions concerning the ben-
efits of surgery, chemotherapy and/or radiotherapy for
individual patients. However, patients with the same
tumour stage frequently demonstrate differing clinical
courses. Hence, there is a need for additional markers
of prognostic significance that could for example,
identify those patients with the highest likelihood of
post-surgical recurrence who might benefit most from
adjuvant chemotherapy (Fig. 1), or alternatively to
recognise those patients with advanced disease who
are unlikely to get sufficient survival benefit to justify
the morbidity of chemotherapy in a palliative setting.
Computed Tomography (CT) plays a key role in
staging of NSCLC, either as a stand-alone technique
or during Positron Emission Tomography, and the
use of CT to provide additional prognostic markers
can form a natural extension to this role. Deriving
markers of prognosis from existing CT images avoids
the cost and radiation exposure associated with tech-
niques such as perfusion CT that require specialised
data acquisitions. CT texture analysis (CTTA) is an
image processing method that can be applied to rou-
tinely acquired images to provide additional quantita-
tive information about tumour heterogeneity as
reflected by the distribution of pixel values within the
tumour. Tumour heterogeneity is an important bio-
logical characteristic related to tumour aggression and
response to treatment. There is an increasing body of
evidence demonstrating the ability of CTTA to pro-
vide prognostic information for patients with NSCLC
and other tumours [1–5].
Integration of CTTA into clinical workflow
At present, none of the currently available image
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software packages has integrated CTTA into their
products. A stand-alone software that implements the
filtration/histogram method is available commercially
(Fig. 2) but needs to be interfaced with the software
used for routine radiological diagnosis. A DICOM ex-
port function is a suitable and commonly available
option but other arrangements are feasible. Because
manual segmentation from the mediastinum, chest
wall or adjacent consolidated lung is required for ana-
lysis for some tumours, CTTA is best performed by
the reporting radiologist. Therefore, CTTA software
needs to be installed on the same workstation as that
used for routine image review or available on a separ-
ate but immediately adjacent workstation. This ar-
rangement also allows the results of CTTA to be
included within the conventional report of the images
undergoing analysis, ensuring clinical immediacy and
relevance. An ability to display CTTA results at the
multi-disciplinary meeting at which treatment deci-
sions are made enables CTTA to be integrated with
other clinical and pathological information. At our in-
stitution, the lung cancer registry software has been
modified to incorporate CTTA results.
Image selection
Although any CT image can in principle be analysed
using CTTA, at our institution we currently restrict
analysis to the low-dose CT (LDCT) component of
Positron Emission Tomography (PET)/CT examina-
tions for the following reasons: Firstly, the prognostic
value of CTTA in NSCLC has been more extensively
clinically validated for LDCT than for diagnostic CT
images, including derivation and testing of cut-off
values from separate patient cohorts [6]. Secondly,
CTTA results can be affected by reconstruction pa-
rameters [7] which are more likely to be varied in
clinical routine for diagnostic CT than LDCT.
Thirdly, the PET images can be useful in guiding the
delineation of tumour margins, particularly when ad-
jacent to pulmonary consolidation. Finally, the deriv-
ation and reporting of quantitative image biomarkers
requires a critical approach to image analysis that is
often more established within nuclear medicine.
Region of interest construction
The single CT slice that displays the largest cross-
section of the tumour is selected for analysis and
Fig. 1 The potential for prognostic biomarkers to stratify care for
patients with NSCLC. CT showing left upper lobe NSCLC at initial
staging a. Based on current practice, the patient underwent surgery
without adjuvant chemotherapy. CT performed 25 months later
shows local recurrence b. A biomarker deployed at staging may
have categorised the patient as high-risk for recurrence, implying a
potential benefit from adjuvant chemotherapy
Fig. 2 Summary of the filtration-histogram method for CTTA. The
conventional CT image (top) is filtered to highlight objects of a
pre-selected size. The distribution of tumour features within the filtered
image as assessed using standard statistical parameters derived from
the corresponding histogram, provides an indication of prognosis
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displayed in soft-tissue windows. When constructing
the tumour region of interest (ROI), automated seg-
mentation procedures should be used wherever pos-
sible to optimise consistency in analysis between
operators. Computer automated segmentation of
tumour relative to aerated lung is straightforward.
When a tumour is completely surrounded by aerated
lung, segmentation tools allow the operator to con-
struct a ROI beyond the tumour edge within which
the precise tumour margins are defined by the soft-
ware algorithm (Fig. 3). However, if the tumour is in
contact with chest wall, mediastinum, pleural fluid or
consolidated lung, the operator must manually define
the tumour soft-tissue interface accurately, erring on
the inside of the tumour. For the remaining borders
where tumour is in contact with aerated lung, this
section of ROI can be drawn within the lung (i.e. out-
side the tumour) leaving the segmentation algorithm
to complete the definition of the tumour edge auto-
matically. The use of narrow CT windows (e.g. level:
40HU, width 150HU) and reference to fused PET/CT
images can assist the definition of tumour boundaries
(Figs. 4 and 5). Areas of tumour cavitation visible on
CT should not be included within the ROI but may
be excluded by segmentation tools (Fig. 4). Areas that
are necrotic on FDG-PET (seen as central photopae-
nia) but exhibit soft-tissue density on CT should be
included within the ROI as there is currently no data
available to indicate the likely impact of excluding
such areas on the derived CTTA values (Fig. 5).
Reporting
CTTA software typically returns a range of texture
parameters for the constructed tumour ROI. For the
filtration-histogram CTTA approach, these parameters
characterise the histogram of pixel intensity values
within the ROI for a series of filtered images
highlighting features of a specified size. Each param-
eter has a different relationship with the size, number,
Fig. 3 When using automatic segmentation for tumour Regions of
Interest (ROIs), the initial manually constructed ROI (a) can include
surrounding lung. The segmentation software then redifines the ROI
to exclude lung tissue b. The filtered tumour image (c) is used for
derivation of texture parameters by histogram analysis
Fig. 4 Left lower lobe NSCLC showing cavitation and adjacent
consolidation. The fused FDG-PET/CT image (a) and narrow CT
windows (b) can assist identification of the tumour margins. Using
automatic segmentation, the initial manually constructed ROI (b)
includes adjacent lung and the area of cavitation but excludes the
adjacent mediastinal structures and pulmonary consolidation. The
final ROI defined by the automated segmentation procedure (c)
exlcudes the adjacent lung and area of cavitation. The final filtered
tumour image is shown in (d)
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brightness and variability of features in the original
CT image [8]. A choice needs to be made as to
which of these parameters should be included in the
final report along with their respective cut-off values
defining good and poor prognosis. This choice can be
based on previously published reports, ideally con-
firmed by a retrospective analysis of a local cohort of
patients. On this basis, we currently report kurtosis
and entropy values for filtered images highlighting ob-
jects of 4 mm radius, indicating that positive kurtosis
and/or an entropy value of > 4.57 are associated with
poorer survival.
Quality assurance & audit
CTTA parameters reflect variations in x-ray attenu-
ation (measured in Hounsfield Units) within the
tumour. The accuracy of CT attenuation values is
checked as part of the routine quality procedures rec-
ommended by the equipment manufacturers. Never-
theless, the potential sources of variability in CTTA
values between different sites have not been fully
characterised. It is therefore essential to audit the
prognostic performance of results acquired locally be-
fore full implementation of CTTA as a biomarker in
clinical practice. If the audit indicates that selection
of different CTTA parameters and/or adjustment of
cut-off values is required to optimise prognostic per-
formance, new cut-off values should be determined
from one patient cohort and tested in another. Alter-
natively, a cross-validation procedure may be used
[6]. Auditing of CTTA results is also required after
change of CT X-ray tube or installation of a new
system.
Clinical engagement
Acceptance of prognostic imaging biomarkers by cli-
nicians is an essential pre-requisite to adoption into
clinical practice and communication of a convincing
case for the use of CTTA as a marker of prognosis is
important for achieving clinical engagement. A “black
box” approach which fails to enunciate the biological
basis of the imaging biomarker values is unlikely to
be successful even in the presence of compelling data
linking the measurements to prognosis. In NSCLC,
emerging evidence that points to the intra-tumour
heterogeneity reflected by CTTA as being a pheno-
typic consequence of activation of the MAPK tumour
pathway provides a clinically and therapeutic relevant
foundation for CTTA as a prognostic indicator. Stud-
ies have shown CTTA values in NSCLC to be related
to hypoxia, mutations in EGFR and KRAS genes, and
ALK gene re-arrangements [3, 5, 9–12], all processes
with links to the MAPK pathway which in turn, has
an established relationship with survival (Fig. 6).
Current works in progress has identified a correlation
between kurtosis values in NSCLC and expression of
the mucin production gene, Mucin5AC, which is con-
sidered a marker of MAPK pathway activation. As
mucin produces lower attenuation of x-rays than soft-
tissue, this association has disclosed a plausible
Fig. 5 Right lower lobe NSCLC showing necrosis without cavitation
(photopaenia on FDG-PET/CT) and adjacent pulmonary consolidation
(a). Due to minimal contact with aerated lung, the tumour ROI has been
constructed manually (b), using the fused PET/CT image and narrow
windows for guidance. The area of necrosis without cavitation is
included in the the ROI and the final filtered tumour image (c)
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connection between the MAPK pathway and CT sig-
nal in NSCLC.
Conclusion
The use of quantitative imaging to provide prognostic
information is a new and exciting development within
cancer imaging that can expand the imaging special-
ist’s existing role in qualitative and semi-quantitative
assessments of prognosis such as TNM staging and
changes in tumour appearances during serial imaging.
Parallel developments are occurring, or have already
emerged, in other areas of imaging such as CT coron-
ary calcium scoring for risk-assessment in patients
with coronary artery disease. Cancer patients often
need to undergo a range of investigations and there is
a responsibility to maximise the clinically relevant in-
formation obtainable from these procedures, particu-
larly when they entail ionising radiation. Derivation of
prognostic information through the application of
image processing techniques such as CTTA, to
images acquired as part of routine care can help im-
aging specialists make best use of the technologies
they deploy for the benefit of patients with cancer.
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